- GSK Vaccines
The signature of this tripartite manufacturing agreement in March 2014 between ARABIO, GSAL and GSK Vaccines establishes a long-term alliance for the manufacturing of GSK Vaccines in Saudi Arabia.
The scope of the alliance is the appointment of ARABIO as a contract manufacturer for the filling and packaging of selected liquid vaccines in prefilled syringes and vials for supply to the member countries of the Gulf Cooperation Council. In addition to the partnership developed in 2010 between GSK Vaccines and GSAL for the manufacturing and commercialization of vaccines in Saudi Arabia, the extension of this partnership to ARABIO will allow GSAL to commercialize in Saudi Arabia GSK Vaccines locally manufactured (filled and packed) by ARABIO.
As such, all GSK Vaccines needed for the Universal Vaccination Program of the Kingdom will be manufactured in Saudi Arabia either by GSAL or by ARABIO.
Novartis Vaccines signed in December, 2009 a License agreement with ARABIO for the manufacturing (Packaging & Filling) & commercialization and supply of selected vaccines in Saudi Arabia and other Middle East markets.
With the signature of this License Agreement, Arab Company for Pharmaceutical Products (ARABIO) and Novartis Vaccines will establish a long-term alliance for the manufacturing (fill & pack) and commercialization of Novartis vaccines in Saudi Arabia and Middle East markets (representing a population of 300 million people).
Novartis will help Arabioto develop a robust vaccines manufacturing capability in Saudi Arabia, improve sustainability of vaccines supply to support vaccination programs of the Arab world.
The manufacturing operations at ARABIO will be implemented in a phased manner; packaging operations will be implemented first and will then be followed by filling operations. First commercial packaging operations were started at the mid-2011 and first commercial filling operations by middle of 2015.
Pursuant to the license agreement, Novartis Vaccines will provide technical support and know-how to ARABIO with regards to manufacturing processes, including training of local employees.
Further to this License Agreement, ARABIO will manufacture up to 3 Novartis Vaccines under the marketing authorization of ARABIO.
BioFarmabecame one of few manufacturers of the world’s vaccines that have WHO qualification, so Bio Farmais trusted to supply the vaccine needs in more than 122 countries. Bio Farmais continually innovating in many areas while referring to international standards and maintaining a current quality management system. Since 1997, Bio Farmais one of 23 manufacturers of vaccines worldwide who have earned the WHO Prequalification. Bio Farmaalso has been certified GMP (Good Manufacturing Practice) by the National Agency of Drug & Food Control (NADFC), Quality Management System ISO 9001: 2008, ISO 14001:2004 and OHSAS 18001: 2007.
In 2014, Arabioand Biofarmasigned a license agreement , With the signature of this License Agreement, Arab Company for Pharmaceutical Products (ARABIO) and BioFarmawill establish alliance for the manufacturing (fill & pack) and commercialization of BioFarmavaccines in Saudi Arabia and Middle East markets (representing a population of 300 million people).
InterVaxis a highly specialized company in the supply of vaccines, antitoxins, diagnostic and plasma products. Headquartered in Toronto, Canada since 1986, InterVaxhas forged many successful collaborations and alliances with well-established manufacturers to offer an extensive line of products all available from a single source.
InterVaxprides itself on its top-rated customer service and the ability to rapidly adapt to evolving market conditions. InterVax'scustomers recognize the continuity of its presence as a competitively priced and highly knowledgeable supplier in a constantly changing industry.In 2012, Arabioand Biofarmasigned a license agreement With the signature of this License Agreement, Arab Company for Pharmaceutical Products (ARABIO) and INTERVAX will establish alliance for the manufacturing (fill & pack) and commercialization of INTERVAX vaccines in Saudi Arabia and Middle East markets (representing a population of 300 million people).